BOSTON, Sept. 5, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced that IFM Due, an IFM subsidiary company, has reached a collaboration and exclusive option agreement with Novartis to develop a suite of immunotherapies that i

OLDWICK, N.J., Sept. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019

CARY, N.C. and BASEL, Switzerland, Sept. 5, 2019 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug developm

CAMBRIDGE, Mass., Sept. 5, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced the appointment of Fred Driscoll to its Board of Directors.  Mr. Driscoll brings to SmartPharm's Boa

LAVAL, QC, Sept. 5, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today an

REHOVOT, Israel, Sept. 5, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that  Yehiel Tal, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on 

WESTON, Fla., Sept. 5, 2019 /PRNewswire/ -- ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for inflammatory and renal diseases, is pleased to announce significant advancements in development of our lead inflammasome inhibitor candidate, IC 100.  IC 100 is a novel monoclonal antibody that inhibits the

AUSTIN, Texas, Sept. 5, 2019 /PRNewswire/ -- Superior HealthPlan has made telehealth services available to nearly 1.3 million members who are covered through the health plan statewide. The service will expand access to healthcare for Superior members while removing transportation and geographic barriers to care. "While Superior offers an expansive provider ne

BLOOMFIELD, Conn., Sept. 5, 2019 /PRNewswire/ -- Breakthrough, potentially life-changing medicines offer great promise for patients and their families. However, the high prices of the medicines – millions of dollars in some cases – threaten coverage and access by patients who may benefit. Experience the interactive Multichannel News Release here:

COLUMBIA, M.D., Sept. 5, 2019 /PRNewswire/ -- ACell, Inc. today announced the launch of their new product, Gentrix® Hiatal at the 2019 Society of Laparoendoscopic Surgeons (SLS) Minimally Invasive Surgery Week 2019 (MISWeek 2019) in New Orleans, Louisiana. Gentrix Hiatal provides physicians a new solution for hiatal